Physician profile
David Levitt
NPI 1497020564
$8,278.81
in general payments reported to CMS, 2019-2025
40 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $209 · 2021: $208 · 2022: $359 · 2023: $1,001 · 2024: $4,634 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,151 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,356 · Consulting Fee: $1,625 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,150.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,356.25 |
| Consulting Fee | $1,625.00 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,126.89 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $601.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $540.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $294.45 | 2019-2025 | |
| Cequr Corporation | $195.33 | 2022-2025 | Cequr Simplicity |
| Radius Health, INC. | $177.29 | 2019-2025 | Tymlos |
| Dexcom, INC. | $172.75 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $165.58 | 2019-2025 | Repatha, Evenity, Tepezza |
| Xeris Pharmaceuticals, INC. | $144.08 | 2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $141.70 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.78 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $138.24 | 2022-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $125.95 | 2021-2025 | |
| Abbvie INC. | $117.54 | 2024-2025 | |
| Madrigal Pharmaceuticals | $110.97 | 2025 | Rezdiffra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $105.82 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $92.60 | 2019-2025 | Xyosted |
| Alexion Pharmaceuticals, INC. | $90.26 | 2022-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $84.98 | 2024-2025 | Unithroid |
| Horizon Therapeutics Plc | $60.26 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $56.49 | 2019-2021 | |
| Lifescan, INC. | $55.07 | 2021-2022 | |
| Esperion Therapeutics, INC. | $52.76 | 2025 | Nexletol |
| Sequel Med Tech, LLC | $49.97 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $48.42 | 2025 | |
| Ascensia Diabetes Care US INC. | $47.67 | 2022-2023 | |
| Medtronic, INC. | $44.11 | 2024-2025 | Minimed 780g |
| Mannkind Corporation | $42.44 | 2020-2023 | Afrezza |
| Amarin Pharma, INC. | $41.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.46 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.37 | 2024 | Crysvita |
| Ibsa Pharma INC. | $21.74 | 2023 | Licart, Tirosint |
| Grt US Holding, INC. | $18.61 | 2022 | |
| Recordati_rare_diseases_inc. | $18.48 | 2025 | Isturisa |
| Amphastar Pharmaceuticals, INC. | $17.51 | 2024 | |
| Zealand Pharma US, INC. | $14.61 | 2021 | |
| Tolmar, INC. | $13.79 | 2024 | |
| Currax Pharmaceuticals LLC | $13.24 | 2024 | Contrave |
| Valeritas, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.